メインのコンテンツにスキップする

申し訳ございませんが、お客様のブラウザには完全に対応しておりませんオプションがありましたら、新しいバージョンにアップグレードするか、 Mozilla Firefox、 Microsoft Edge、Google Chrome、またはSafari 14以降をお使いください。これらが利用できない場合、またサポートが必要な場合は、フィードバックをお送りください。

Elsevier
論文を投稿する
Press release

New Elsevier report suggests 63% of R&D organizations have made important decisions with flawed data

2026年11月12日

Global Corporate R&D of the Future report reveals a paradox at the heart of R&D decisions: confidence in data is high, but gaps in quality and connection persist

R&D teams are confident in their evidence, yet report making decisions based on flawed or incomplete data, according to Elsevier’s Corporate R&D of the Future report, a global survey of more than 1,000 R&D leaders, managers and researchers at R&D-led corporations.

More than three quarters (76%) of respondents are confident in the quality of their data. Yet 63% of those who answered say their organization has at some point made an important R&D decision using data or evidence later found to be inaccurate, incomplete or outdated. About half (51%) say their organization has had to make an important R&D decision before all the evidence was in.

The survey findings show AI is moving into R&D decision-making, but expectations are running ahead of use: 81% expect AI to fundamentally transform how R&D decisions are made over the next five years, yet under half (47%) say it is used regularly in their organization’s R&D function today.

Stuart Whayman, President, Corporate Markets at Elsevier, commented, “Confidence is not the same as accuracy. R&D teams are under pressure to decide faster, and often before all the evidence is in. Confidence keeps them moving, but it can't make up for evidence that is incomplete, outdated or unreliable. AI will raise the stakes, because it will amplify whatever evidence it is given, good or bad. The advantage will go to the organizations that can bring their evidence together and trace and verify what sits behind their decisions.”

Key findings

The report looks at how R&D teams use data and evidence to make decisions, where that evidence comes from, how well it is connected, and how AI is being applied and trusted.

  • Access is not enough. 78% have access to the third-party evidence they need, yet more than half (56%) of those still report at least one barrier. Across all respondents, the top barriers are scattered sources (42%), slow finding and synthesis (32%) and not knowing what evidence exists (30%).

    • Respondents in APAC (90%) are most likely to have access to third-party evidence, compared to 73% in North America and 77% in Europe.

  • AI is common, but not yet routine. 47% say AI is used regularly in their organization’s R&D, and a further 40% say it is being piloted. Personally, most respondents use AI across a range of R&D activities, led by data analysis (71%), literature search (70%), and competitive intelligence (70%).

  • Trusted evidence is seen as the AI advantage. 86% believe organizations that combine AI with trusted, high-quality evidence will outperform those that do not.

  • Compliance, ease of use and accuracy are among the top factors that would increase willingness to use AI. 55% select AI that complies with laws and regulations, 54% AI that is easy to use and integrates with workflows, and 54% AI trained for factual accuracy and safety.

    • Compliance is a bigger draw in Europe. Among all respondents, 64% in Europe say they would be more willing to use AI if it complies with laws and regulations.

  • Scaling AI divides opinion. 48% say implementing AI at scale will be a significant challenge. The priorities selected most often for the next five years are building AI skills across the organization (65%), turning data and evidence into actionable insights (62%), and tailoring AI to organizational knowledge and workflows (59%).

    • Scaling is seen as a challenge more in North America. Among all respondents, 56% in North America say implementing AI at scale will be a significant challenge, against 50% in Europe and 34% in APAC.

  • General-purpose tools lead for literature search. Of those answering, 48% use general-purpose AI tools such as ChatGPT or Copilot for literature search, against 23% who use specialist scientific AI tools. For data analysis and modeling, specialist tools are the most common choice.

Elsevier’s research also reveals regional differences in how R&D leaders and managers view their evidence and AI:

Share of R&D leaders and managers who…

North America

Europe

APAC

Say evidence that is not robust or reliable enough reduces their confidence

42%

32%

23%

Agree that implementing AI at scale will be a significant challenge

52%

43%

28%

Say AI-generated summaries or outputs are essential evidence

30%

36%

61%

Would be more willing to use AI if it complies with laws and regulations

43%

62%

47%

Bases (R&D leaders and managers): North America n=183, Europe n=234, APAC n=275. Don’t know answers are excluded, so bases vary slightly by question. South America (n=34) and the Middle East & Africa (n=33) are not shown because of small samples.

The full Corporate R&D of the Future report, which also compares views by region, organization size and role and sets out recommendations for R&D organizations, is available at www.elsevier.com/insights/corporate-r-and-d-of-the-future.

About the survey

Corporate R&D of the Future is based on an online survey, conducted by email invitation between August and October 2026, of 1,038 R&D leaders, managers and researchers at R&D-led corporations in 55 countries across North America, South America, Europe, the Middle East and Africa, and Asia Pacific. Responses are weighted. Figures may not sum up because of rounding. Full methodology is in the report appendix. Figures on flawed decisions exclude respondents who answered don’t know or preferred not to say.

エルゼビアについて

エルゼビアは、先端情報と意思決定支援の分野におけるグローバルリーダーです。1世紀以上にわたり、科学と医療の発展を通じて人類の進歩に貢献してきました。世界170か国において、学術・企業の研究コミュニティ、医師、看護師、将来の医療従事者、教育関係者の重要な活動を支援しています。エルゼビアは、世界有数のエビデンスに基づく科学・医学コンテンツ、精度の高いAI、そして専門家による評価を基盤とした研究・臨床レベルのソリューションを提供し、より良い成果の実現を支援しています。また、サービスを提供するコミュニティと連携しながら、多様性とサステナビリティの推進にも取り組んでいます。エルゼビア財団opens in new tab/window(Elsevier Foundation)は、世界各地における研究および医療分野のパートナーシップを支援しています。

エルゼビアは、専門家およびビジネス向けの情報分析および意思決定ツールを提供するグローバル企業、RELXopens in new tab/windowの一員です。詳細については、https://www.elsevier.com/ja-jp をご覧いただくか、ソーシャルメディアの @elsevierconnect をご参照ください。

連絡先

Mathew Pitt-Bailey Headshot

Mathew Pitt-Bailey

Director, Industry Markets

Elsevier

+44 (0) 7353 890 322

E-mail Mathew Pitt-Bailey